Who
Faheem Hasnain
President & CEO
Company insider
Files Form 4 as: President & CEO, Gossamer Bio; Director, Kura Oncology; Director, Mirati Therapeutics; Director, Nuvation Bio; Director, Forte Biosciences; Director, Immunic; President & CEO, Receptos; Director, Ambit Biosciences.
In numbers
- Trades disclosed
- 230
- Buys
- 12
- Sells
- 12
- Bought
- $5.9M
- Sold
- $26.4M
- Companies
- 13
- Companies where not an officer
- 8
- First trade
- 6 Feb 2006
- Last trade
- 24 Aug 2026
- Last filed
- 26 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | $166K166 at $1,000.00 | filing |
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —5,800,051 at $0.00 | filing |
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | $166K166 at $1,000.00 | filing |
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —5,800,051 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,680,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —43,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —1,680,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —1,540,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —1,312,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —437,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —544,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —544,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —325,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —47,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,540,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —43,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,312,500 | filing |
News
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesKURA · manilatimes.net · 13 Oct 2026Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in DiabetesKURA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Faheem Hasnain; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.